OraSure Technologies, Inc. (NASDAQ:OSUR) insider Brian Smith sold 3,075 shares of the business’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $21.09, for a total value of $64,851.75. Following the completion of the sale, the insider now owns 24,540 shares of the company’s stock, valued at approximately $517,548.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of OraSure Technologies, Inc. (NASDAQ:OSUR) traded down 1.46% during trading on Friday, reaching $20.28. 495,538 shares of the company were exchanged. OraSure Technologies, Inc. has a 1-year low of $7.09 and a 1-year high of $21.59. The stock has a market capitalization of $1.21 billion, a P/E ratio of 37.49 and a beta of 1.57. The firm has a 50-day moving average price of $19.36 and a 200-day moving average price of $14.91.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.02. OraSure Technologies had a net margin of 22.29% and a return on equity of 15.64%. The company had revenue of $40.18 million during the quarter, compared to analyst estimates of $36.54 million. During the same quarter in the prior year, the business earned $0.07 earnings per share. The business’s quarterly revenue was up 28.1% compared to the same quarter last year. Equities research analysts predict that OraSure Technologies, Inc. will post $0.48 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/08/27/insider-selling-orasure-technologies-inc-osur-insider-sells-64851-75-in-stock.html.

A number of analysts recently issued reports on OSUR shares. Zacks Investment Research upgraded OraSure Technologies from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a report on Saturday, May 6th. Jefferies Group LLC boosted their price target on OraSure Technologies from $12.00 to $16.00 and gave the company a “buy” rating in a report on Thursday, May 4th. Stephens reiterated an “overweight” rating and issued a $19.00 price target (up previously from $14.00) on shares of OraSure Technologies in a report on Tuesday, July 11th. Canaccord Genuity boosted their price target on OraSure Technologies from $15.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, June 28th. Finally, BidaskClub lowered OraSure Technologies from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. OraSure Technologies currently has an average rating of “Buy” and a consensus price target of $15.46.

Several hedge funds and other institutional investors have recently made changes to their positions in OSUR. USA Financial Portformulas Corp increased its position in shares of OraSure Technologies by 31.0% in the second quarter. USA Financial Portformulas Corp now owns 56,653 shares of the medical instruments supplier’s stock valued at $978,000 after buying an additional 13,421 shares during the period. Advisory Services Network LLC increased its position in shares of OraSure Technologies by 1,419.2% in the second quarter. Advisory Services Network LLC now owns 12,913 shares of the medical instruments supplier’s stock valued at $223,000 after buying an additional 12,063 shares during the period. Public Employees Retirement System of Ohio purchased a new position in shares of OraSure Technologies during the second quarter valued at $5,119,000. Koch Industries Inc. purchased a new position in shares of OraSure Technologies during the second quarter valued at $216,000. Finally, Piedmont Investment Advisors LLC purchased a new position in shares of OraSure Technologies during the second quarter valued at $216,000. Institutional investors and hedge funds own 89.76% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Insider Buying and Selling by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Stock Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related stocks with our FREE daily email newsletter.